AXIM Biotech Retains ORA to Manage Glaucoma & Dry Eye Indications Product Development and Clinical Trials

Source: AXIM Biotech

Wednesday, March 22, 2017 | Glaucoma , Partnerships , Ora


Axim Biotechnologies is retaining the services from contract research organization Ora to run the company’s upcoming product development and clinical trials for the treatment of glaucoma and dry eye patients utilizing cannabinoid-based therapeutics.

The clinical trial will run under the supervision AXIM Advisory Board Member Prof. Robert Ritch who is the Surgeon Director Emeritus and Chief of Glaucoma Services at New York Eye and Ear Infirmary of Mount Sinai School of Medicine in New York. He has devoted his career to broadening our understanding of the underlying etiologies and mechanisms of glaucoma and innovation in its medical, laser, and surgical treatment.
 
 


Comments

You must be logged in to leave a comment.